SNDY Could Dish Out Even Bigger Gains Than It Gave Us Last Week. Did You Prepare?
All aboard the money train!
One of the best ways to profit as a trader is to revisit a stock that has helped you profit before. That’s because you get experience with the stock’s trading channels and you see how insiders treat the stock as well.
That’s why today’s pick is crucial to your trading success. I alerted this stock on Tuesday of last week and my conservative estimate was that the stock could gain 50% in one day. Well, it did even better than that and produced profits of 66%… in one day!
This time it looks like it could do even better as the stock has pulled back to 5 cents a share and still has the same share price as a ceiling. So get ready because today we could be in for gains of more than 100%!
Solos Endoscopy, Inc. (OTCPINK: SNDY)
SNDY is trading with a solid 51 RSI on the daily chart which means momentum is building fast.
Currently entry is around 5 cents but consider that a bargain because in the last 12 months SNDY has traded as high as .15!
I don’t know about you but upside potential of up to 200% is very enticing. Plus, daily volatility is racing north so it looks like investors are about to pile into this 5-cent gem a little more.
And did I mention the news?
SNDY announced last week that it’s renewed its registration with the FDA. This means the company’s line of medical devices is legit as far as the biggest regulator in the US is concerned.
Talk about a vote of confidence.
At any rate this is a solid opportunity and one I hope you don’t let slip through your fingers.
Remember, this a company that has added 1633% to its historical lows – and it’s just getting started based on what I can see.
Check out the chart…
Here’s a link to the chart: http://www.barchart.com/interactive_charts/stocks/SNDY
SNDY (Solos Endoscopy, Inc.) is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office.
US Medical Device Set To Reach $133 Billion By The End Of 2016
The United States remains the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016. The U.S. market value represented about 38 percent of the global medical device market in 2012. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $44 billion in 2012, a more than 7 percent increase from the previous year.
There are more than 6,500 medical device companies in the U.S., mostly small and medium-sized enterprises (SMEs). More than 80 percent of medical device companies have fewer than 50 employees, and many (notably innovative start-up companies) have little or no sales revenue. Medical device companies are located throughout the country, but are mainly concentrated in regions known for other high-technology industries, such as microelectronics and biotechnology. The states with the highest number of medical device companies include California, Florida, New York, Pennsylvania, Michigan, Massachusetts, Illinois, Minnesota and Georgia. Other states with significant sector employment include Washington, Wisconsin, and Texas.
Solos Endoscopy, Inc. Renews FDA Registration
SNDY announced that the company has renewed the Establishment Registration & Device Listing of its endoscopic instruments with the U.S. Food and Drug Administration (FDA).
Solos Endoscopy instruments are registered and approved with the FDA; the FDA approval also covers the entire MammoView® instrument line. The company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.
Solos Endoscopy recently completed a capital restructuring initiative in order to position itself for growth over the next twelve months. The Company plans to raise capital in order to fulfill outstanding purchase orders and pursue international sales initiatives.
“Management believes that renewal of its establishment registration with the FDA along with the capital restructuring was necessary to maintain the value of our company and position us for growth. Solos has been recognized nationwide by physicians who use their instruments. It is our hope that this recognition will lead to increased sales worldwide,” stated Robert Segersten, President Solos Endoscopy.
To learn more about SNDY please visit their website: http://www.solosendoscopy.com/
Make your move on SNDY now.
We have been compensated $10k cash via bank wire by a third party, ACN, LLC, to conduct investor relations advertising and marketing for SNDY. Stellar Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.